Acetohydroxamic acid
Enzyme inhibitor that inhibits urease
From Wikipedia, the free encyclopedia
Acetohydroxamic acid (also known as AHA or by the trade name Lithostat) is a drug that is a potent and irreversible enzyme inhibitor of the urease enzyme in various bacteria and plants; it is usually used for urinary tract infections and urinary stone disease. The molecule is similar to urea but is not hydrolyzable by urease;[1] it thus disrupts the bacteria's metabolism through competitive inhibition. It is particularly effective for the prevention and treatment of infection stones (stuvite stones).[2]
| |
 | |
| Clinical data | |
|---|---|
| Trade names | Lithostat |
| AHFS/Drugs.com | Consumer Drug Information |
| Pregnancy category |
|
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.008.104 |
| Chemical and physical data | |
| Formula | C2H5NO2 |
| Molar mass | 75.067 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Orphan drug
In 1983 the US Food and Drug Administration approved acetohydroxamic acid (AHA) as an orphan drug for "prevention of so-called struvite stones" under the newly enacted Orphan Drug Act of 1983.[3] AHA cannot be patented because it is a standard chemical compound.[3]